Resources from the same session
2359O - Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
Presenter: Arlene Siefker-Radtke
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA102 - THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment
Presenter: James Catto
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 2359O and LBA102
Presenter: Michiel van der Heijden
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Webcast
2360O - The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA103 - ICRA: Efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1
Presenter: Sarah M.H. Einerhand
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Webcast